<DOC>
	<DOCNO>NCT01150162</DOCNO>
	<brief_summary>A Prospective Randomized , Multi-center study ass Safety Efficacy Mucosta ( Rebamipide ) , combination Omeprazole adjuvant therapy Gastric Ulcer Patients .</brief_summary>
	<brief_title>Mucosta Gastric Ulcer Treatment , Effectiveness Safety Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>Patients dyspepsia epigastric pain endoscopically proven gastric duodenal ulcer Required laboratory parameter time limit ( screen blood test take include hemoglobin , white blood cell count , random glucose , potassium , sodium , chlorine , creatinine , AST , ALT , bilirubin , alkaline phosphatase ) Age &gt; 18 year A statement patient must sign informed consent form prior registration study Patients undergone surgery ulcer History hypersensitivity drug use study Women pregnant lactating intend get pregnant study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>